Bridgefront Capital’s Biogen BIIB Stock Holding History

Bridgefront Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1M	Buy	+6,010	New	+$1.11M	0.27%	111
2025 Q4	–	Sell	-1,962	Closed	-$275K	–	536
2025 Q3	$275K	Buy	+1,962	New	+$265K	0.08%	425
2025 Q2	–	Sell	-5,275	Closed	-$722K	–	616
2025 Q1	$722K	Buy	+5,275	New	+$754K	0.21%	158
2024 Q4	–	Sell	-3,243	Closed	-$629K	–	587
2024 Q3	$629K	Buy	+3,243	New	+$678K	0.24%	132
2023 Q3	–	Sell	-975	Closed	-$278K	–	403
2023 Q2	$278K	Buy	+975	New	+$290K	0.15%	276
2023 Q1	–	Sell	-1,445	Closed	-$400K	–	424
2022 Q4	$400K	Sell	1,445 -144	-9%	-$40.7K	0.28%	140
2022 Q3	$424K	Buy	+1,589	New	+$337K	0.43%	62

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bridgefront Capital's BIIB Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Biogen (BIIB) in Q1 2026: 6,010 shares worth $1.1M. The stake represents 0.27% of the portfolio and ranks #111 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in BIIB as recently as Q3 2025.

Bridgefront Capital first reported a position in BIIB in Q3 2022 and has held it in 7 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Bridgefront Capital held 6,010 shares of Biogen worth $1.1M as of Q1 2026.
Biogen was a new Bridgefront Capital position in Q1 2026.
Biogen made up 0.27% of Bridgefront Capital's portfolio in Q1 2026, its #111 holding.
Bridgefront Capital first reported a position in Biogen in Q3 2022 and has held it in 7 quarters since.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.